FDC · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 39/100 — Quality 58 · Valuation 29 · Momentum 11
| Share price | ₹417.90 |
| Market cap | ₹7,038 Cr |
| P/E ratio | 25.0 |
| P/B ratio | 2.8 |
| ROCE | 14.9% |
| Dividend yield | 2.31% |
| Book value | ₹152.62 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,171 Cr | ₹281 Cr | 16.0% |
| 2025 | ₹2,108 Cr | ₹267 Cr | 15.0% |
| 2024 | ₹1,943 Cr | ₹305 Cr | 17.0% |
| 2023 | ₹1,784 Cr | ₹194 Cr | 14.0% |
| 2022 | ₹1,525 Cr | ₹216 Cr | 17.0% |
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flav